MabVax Therapeutics Holdings Inc
MabVax Therapeutics — Rodman Conference (September 2016)
32 slides from MabVax Therapeutics's conference presentation, Sep 13, 2016

Slide 1: Corporate Presentation – Rodman Conference
M MabVax —_ therapeutics Immuno-Oncology Products Discovered From The Human Immune Response to Cancer David Hansen President and CEO Corporate Presentation Rodman Conference

Slide 2: Disclaimer
DISCLAIMER Forward Looking Statements This presentation contains forward-looking statements and projections. The company makes no express or implied representation or warranty as to the completeness of this information or, in the case of the projections, as to their attainability or the accuracy and

Slide 3: Key Highlights
KEY HIGHLIGHTS ¢ HuMab Discovery Platform: antibody-based products derived from the human immune response to cancer — Developed platform for antibody discovery resulting in portfolio of fully human antibodies — Integrated approach to development of cancer diagnostics along with therapeutics — Initia

Slide 4: Key Highlights - Corporate and Financial
KEY HIGHLIGHTS - CORPORATE AND FINANCIAL ¢ Uplist to Nasdaq Capital Market — Effective August 17th — Re-IPO (Price — Reverse — Uplist simultaneously) — Stock trading up since re-IPO ¢ Closed $9.4M financing = Underwritten offering by Laidlaw — Significantly oversubscribed — Lead by OPKO and Dr. Fros

Slide 5: Market Opportunity
MARKET OPPORTUNITY According to a GBI Research Report, the global pancreatic cancer treatment will grow from its current level of $1.9 billion to $2.9 billion by 2021. ¢ GBI Research Report forecasted the Colorectal Cancer (CRC) therapeutics market over 2013-2020in 8 major markets that include the U

Slide 6: MabVax Discovery Platform: Therapies Derived From the Natural Human Immune Response
MABVAX DISCOVERY PLATFORM: ‘THERAPIES DERIVED FROM THE NATURAL HUMAN IMMUNE RESPONSE Focused Discovery + Vaccination drives specific immune response * Survey response across multiple patients + Single B-cell interrogation yields novel antibodies + Native human antibodies generated against validated

Slide 7: HuMab-5B1 Demonstrates Integrated Antibody Clinical Development Platform
HUMAB-5B1 DEMONSTRATES INTEGRATED ANTIBODY CLINICAL DEVELOPMENT PLATFORM ‘Therapeutic Antibody (MVT-5873) Demonstrate safety, tolerability as single agent * Phase! trial initiated February 2016 with early read on trial 3Q16 * ClinicalTrials.gov Identifier: NCT02672917 + Clear all dosage levels for f

Slide 8: MabVax Has Rich Pipeline of Product Candidates
MABVAX HAS RICH PIPELINE OF PRODUCT CANDIDATES Program Indication Collaborators Pre-IND Phase1 Phase2 Commercial Discovery Rights Metastatic Pancreatic & NEASKC, QE 7 Ci Cancers ee ww Metastatic Paneeatic & NIWAMSKCC, Ee Cl Cancers aes ww Metastatic Paneeaie ‘MVT-1075 SS) Re py CE MSKCC ww Metatate

Slide 9: Lead Antibody Program – HuMab-5B1
ey he Y HuMab-SB1 Y¥ HoMab-5B1 conjugate # Payload CA19-9 detection in patients * Tumor type Pancreas Stomach Endometrium Uterus Colon/rectum Breast Ovary Other LEAD ANTIBODY PROGRAM — HUMAB-5B1 SLEA ANTIGEN EXPRESSED ON MULTIPLE SOLID TUMOR CANCERS HuMab-5B1 derived from a patient vaccinated with M

Slide 10: Sialyl Lewis A as a Target for Cancer Therapeutics
A SIALYL LEWIS AS A TARGET FOR CANCER THERAPEUTICS # Sialyl Lewis A antigen (CA19-9) is the most frequently utilized and only validated serum a ashes for asserament of pancieitc cancers | Sedan Oy # Aberrant glycosylation results in expression \_ Sialyl Lewis* ic of sLe* and facilitates tumor prolif

Slide 11: HuMab-5B1 Has Ideal Characteristics That Enable Development of Product Platform
HUMAB-5B1 HAs IDEAL CHARACTERISTICS THAT ENABLE DEVELOPMENT OF PRODUCT PLATFORM Characteristic ‘Targeting cancer cell Binds tightly to target cell Cytotoxicity Does not target normal cells Additive effect with chemo therapy Ability to attach additionalagents Benign side effect profile in animal toxi

Slide 12: HuMab-5B1 Specificity
HUMAB-5B1 SPECIFICITY HIGHLY SpEciric To sLE“ ANTIGEN BY GLYCAN ARRAY ANALYSIS Exquisite binding to Sialyl Lewis A structural antigens from a database of 462 antigens! RFU 561 (1OugimL) Slide# 12987 CFGH# 2068 06/25/2010 V4.1 Aloxadss CMZ NeuSAca2-3Gal1-3(Fuca-4)GIcNAcB (NeuSAc-Le?) ——> Neu5Gca2-3Ga

Slide 13: HuMab-5B1 Antibody Target Significantly Overexpressed on Multiple Cancers
HUMAB-5B1 ANTIBODY TARGET SIGNIFICANTLY OVEREXPRESSED ON MULTIPLE CANCERS Potential therapeutic utility extends beyond pancreatic cancer Pancreatic ductal adenocarcinoma Colon carcinoma Lung adenocarcinoma Urinary bladder, mucinous adenocarcinoma Colon metastatic to ovary Breast carcinoma, lymph nod

Slide 14: HuMab-5B1 Potentiation of Anti-Tumor Effect of SOC Chemotherapy in Pancreatic Cancer
HUMAB-5B1 DEMONSTRATES SUBSTANTIAL POTENTIATION OF ANTI- TUMOR EFFECT OF SOC CHEMOTHERAPY IN PANCREATIC CANCER Relative Tumor Growth at Day 42 Gemcitabine/nab-Paclitaxel as Baseline BxPC3 Xenograft Model SOC = Gemeitabin [80mg/kg] and nab-Pactitaxel [20mg/Keg] 8 owth Relative to Control (%) 3 SOC ‘S

Slide 15: HuMab-5B1 Anti-Tumor Effect in Small Cell Lung Cancer Model
HUMAB-5B1 DEMONSTRATES SUBSTANTIAL ANTI-TUMOR EFFECT IN SMALL CELL LUNG CANCER MODEL Potentiation of Tumor Growth Inhibition and Growth Delay Seen When Combined With Chemotherapy 2500 eH gg Somgyig (contra) Mv 5873 25 mash = 2000 | —emavr-se73 50 me/ig £ —+pacttaxel 20 mg/kg @ 3500 | —e_vrser so mg/

Slide 16: MVT-2163 HuMab Immuno-PET Imaging Agent
MVT-2163 HUMAB IMMUNO-PET IMAGING AGENT + Significant unmet medical need for improved diagnosis and monitoring of pancreatic cancer + Preclinical data demonstrate potential for new HuMab-5B1based PET agent + Radiolabel abundant, commercially available, relatively inexpensive, & readily amenable to c

Slide 17: MVT-2163 Improves Imaging Compared to Standard Agent in Use Today
MVT-2163 IMPROVES IMAGING COMPARED TO STANDARD AGENT IN USE TODAY ‘Mice orthotopically transplanted with BxPC3-luc pancreatic tumor xenografts —— ‘The co-egstation of FDG-PET and computed temopaphy (CT) (ef) and phnae sections of FDG-PET only (ight) displayed eninimal tomer detection of the tacer wi

Slide 18: Dual Labeled HuMab-5B1 May Provide Insights During Surgical Resection
DUAL LABELED HUMAB-5B1 MAY PROVIDE INSIGHTS DURING SURGICAL RESECTION * Dual labeled HuMab-5B1 (Zr & NIRF) retains targeting ability * Suite-2 tumors and metastases visualized by PET and UV light * Intra-surgical guidance for tumor resection can become feasible JL. Houghton. Site-specifically labele

Slide 19: MVT-1075 HuMab-5B1 Radioimmunotherapy (RIT)
MVT-1075 HUMAB-5B1 RADIOIMMUNOTHERAPY (RIT) Combines established efficacy of radiation therapy with tumor specific targeting Product has potential to deliver more potent HuMab-5B1 based product "Luis a low-energy radiation emitter with a relatively short tissue penetration range (maximum, 1.6 mm) po

Slide 20: MVT-1075 Radioimmunotherapy Demonstrates Tumor Growth Suppression and Regression
MVT-1075 HUMAB-5B1 RADIOIMMUNOTHERAPY DEMONSTRATES SUBSTANTIAL ‘TUMOR GROWTH SUPPRESSION AND TUMOR REGRESSION Biodistribution_of 177 Lu-CHX-A”-DTPA-5B1 277Lu-CHX-A"-DTPA-5B1 + Control (PBS) 251 & T5yCi + 180 2 a00u6i © 450nCi N=8 for alll groups. Normalized Tumor Volume 0 . 7 men” SF ASL PGES ‘+ slo

Slide 21: MVT-1075 Orthotopic PDAC Model Demonstrates Tumor Regression
MVT-1075 HUMAB-5B1 RADIOIMMUNOTHERAPY OrTHOTOPIC PDAC MODEL DEMONSTRATES TUMOR REGRESSION Pre-treatment Post-treatment Tumor Growth -+ Control (saline) = 177-881 (300 iCi) Tumor Volume (mm?) 0 5 10 15 20 25 Time after RIT Administration (days) Allwedk done incolaboation with andi the Mb of Jason S.

Slide 22: HuMab-5B1 Based Antibody Drug Conjugate (ADC)
HUMAB-5B1 BASED ANTIBODY DRUG CONJUGATE (ADC) ‘Schematic representation of the processes associate with the mechanism of action and biological activity of Antibody deug conjugates ° ° HuMab-5B1 has ideal characteristics for ADC Antibody is readily internalized Large number of targets on each cell Pr

Slide 23: HuMab-5B1 ADC Demonstrates Significant Efficacy in Multiple Tumor Cell Lines
HUMAB-5B1 ANTIBODY DRUG CONJUGATE DEMONSTRATES SIGNIFICANT EFFICACY IN MULTIPLE TUMOR CELL LINES mates | : — went! ites z oe al Internalizationof HuMab-5B1 i i Into BxPC3 Pancreatic Cancer Cells Res Concentration ' a 7 _— — E =e = 0001 ont Ot 7 70 (to : \ ; | ‘mab Concentration (it) = hex aE EE Tena

Slide 24: HuMab-5B1 ADC In Vivo Linker Optimization Study Demonstrates Efficacy
HUMAB-5B1 ANTIBODY DRUG CONJUGATE IN VIVO LINKER OPTIMIZATION STUDY DEMONSTRATES EFFICACY 600.0 7 500.00 4 Mean Tumor Volume Group: PBS (10mI/tg) 2-Groupo2: huS81 AOC: (2g) = Group 03: ns81-A0C2 2re/tg) Group 04: huS81-AOCS (2re/tg) Group 05: huSB1-ADCS (¢me/tg) = Group 06: nuS81-AOCE(2re/te) Group

Slide 25: Early Feedback on MVT-5873
EARLY FEEDBACK ON MVT-5873 PHASE I CLINICAL TRIAL AS THERAPEUTIC AGENT ¢ Objectives of Phase I trial Determine safety and tolerability as a single agent and in combination with chemotherapy as first line therapy Determine recommended Phase 2 dose for both single agent and combination therapy Determi

Slide 26: Early Feedback on MVT-2163
EARLY FEEDBACK ON MVT-2163 PHASE I PET IMAGING CLINICAL TRIAL ¢ Objectives of Phase I trial Determine safety as a single agent and in combination with MVT-5873 as blocking dose Determine recommended dose of MVT-5873 required for optimal tumor visualization Determine optimal time interval between dos

Slide 27: Status on MVT-1075
STATUS ON MVT-1075 PHASE I RADIOIMMUNOTHERAPY CLINICAL TRIAL ¢ Objectives of Phase I trial Determine MTD and safety profile as a single agent Determine dosimetry of MVT-1075 Evaluate tumor response rate and duration of response Define a recommended Phase II dose as a single agent Expand Phase I to i

Slide 28: Key Milestones for HuMab-5B1 Development Program
KEY MILESTONES FOR HUMAB5B1 DEVELOPMENT PROGRAM FOR 2016 AND 2017 Development | 112016 Program ‘MVT-5873 + Initiate dose ‘Therapeutic escalation safety, Meaedieoy Phase I Tial ‘MVT-5873 * Initiate dose Therapeutic escalation safety Combinationwith Searel Tu Chemo MVT-2163 + Initiate dose PET Imagin

Slide 29: Robust Intellectual Property
ROBUST INTEL YTUAL PROPERTY ¢ 11issued patents and 3 pending applications in the U.S. — Issued patents covering monovalent and polyvalent vaccines, methods of manufacture, methods of use — 2 pending applications covering monoclonal antibodies ¢ 14 international patents and 3 pending applications — I

Slide 30: Strong Management Team and Board of Directors
STRONG MANAGEMENT TEAM AND BOARD OF DIRECTORS ——— J. David Hansen Aciig Nenets Bonen, J.DavidHansen ——_Coponte O15 Founder, resident & CEO Does Scheng Plough, Ker, Board Member =e JefferyRavetch, Rosier Uncen, Nason Philip Livingston, M.D. west Sous Ketaiag MD., Ph.D Acadeny of Sects and Insts of Fo

Slide 31: Capitalization Table/Financial Statistics
Capitalization Table/Financial Statistics Average Exercise Price Common Shares - Outstanding - 58M Preferred Stock— Common Equivalents ($0.01 Liquidation = 34M. Preference) Restricted Stock Units — Outstanding and Unvested - 02M. ‘Warrants - Outstanding 36.84 51M Stock Options — Outstanding and Unve

Slide 32: Market Statistics
Market Statistics Price: $5.58 on 628,585 shares traded (9/07/16) 52 Week Range: $3.04 - $12.37* Avg. Daily Vol./Liquidity First 15 Days on Nasdaq: 114,726/$600,000* Shares Outstanding: 5.8 Million* Market Cap: $32.3 Million* Float: 5.5 Million Free Trading Shares Price & Volume quotes from the Nasd
Source: SEC EDGAR · 8-K filed Sep 13, 2016
More decks from MabVax Therapeutics Holdings Inc
Investor Presentation (October 2018)19 slides · Oct 22, 2018
Virtual Investor Conference (May 2018)25 slides · May 3, 2018
Investor Presentation (February 2018)24 slides · Feb 12, 2018
Investor Presentation (September 2017)33 slides · Sep 12, 2017
Investor Presentation (August 2017)33 slides · Aug 24, 2017
Investor Presentation (June 2017)23 slides · Jun 23, 2017